Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference
October 16, 2017 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Oct. 16, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Therapeutics Welcomes Dr. Helen Tayton-Martin to Its Board of Directors
October 11, 2017 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Oct. 11, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results
August 11, 2017 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Aug. 11, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Provides Update on Small Molecule Programs
July 05, 2017 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - July 5, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Announces Partial Exercise of Over-Allotment Option
June 28, 2017 15:45 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - June 28, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Expands Clinical Trial With TTI-621 to Include Combination With PD-1 Blockade
June 07, 2017 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - June 7, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company, today announced that based upon promising...
Trillium Closes US$30 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
June 01, 2017 16:10 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - June 1, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting
May 31, 2017 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - May 31, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Announces Voting Results from the Annual Meeting of Shareholders
May 26, 2017 16:05 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares
May 26, 2017 08:30 ET
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...